As of March 1, 2018, new precertification requirements are in effect
for Independence commercial and Medicare Advantage HMO and PPO members for the
following specialty drugs that are eligible for coverage under the medical
benefit:
- Durolane® (hyaluronic acid)
- IxifiTM (infliximab-qbtx)
- Lutathera (lutetium [177Lu] oxodotreotide)
- OgivriTM (trastuzumab-dkst)
- PemfexyTM (pemetrexed)
- TriViscTM (sodium hyaluronate)
These changes are reflected in an updated precertification requirement list,
which has been posted to our
website.